Afatinib
- Generic Name
- Afatinib
- Brand Names
- Gilotrif, Giotrif
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25ClFN5O3
- CAS Number
- 850140-72-6
- Unique Ingredient Identifier
- 41UD74L59M
- Background
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif . For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by ...
- Indication
Afatinib is a kinase inhibitor indicated as monotherapy for the first-line treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test , and (b) adult pa...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory, metastatic squamous cell Non-small cell lung cancer
- Associated Therapies
- -
Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 320
- Registration Number
- NCT02450656
- Locations
- 🇳🇱
UMC St. Radboud Nijmegen, Nijmegen, Gelderland, Netherlands
🇳🇱Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT02440854
- Locations
- 🇬🇷
Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece
🇬🇷Chest Hospital of Athens "Sotiria", Athens, Greece
🇬🇷University General Hospital of Heraklion, Heraklion, Greece
Safety Study of Afatinib for Brain Cancer
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Santosh Kesari
- Target Recruit Count
- 24
- Registration Number
- NCT02423525
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
Trial of Afatinib in Pediatric Tumours
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02372006
- Locations
- 🇫🇷
INS Curie, Paris, France
🇦🇺Sydney Childrens Hospital, Randwick, New South Wales, Australia
🇫🇷HOP Pellegrin, Bordeaux, France
Afatinib in NSCLC With HER2 Mutation
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 13
- Registration Number
- NCT02369484
- Locations
- 🇨🇭
CHUV, Lausanne, Switzerland
🇨🇭USZ, Zürich, Switzerland
🇳🇱NKI-AVL, Amsterdam, Netherlands
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
- Conditions
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Columbia University
- Registration Number
- NCT02274012
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02208843
- Locations
- 🇷🇴
Sf. Nectarie Oncology Center, Craiova, Craiova, Romania
🇷🇸Institute for Oncol & Radiol of Serbia, Clinic f. Med. Onco., Belgrade, Serbia
🇹🇭King Chulalongkorn Memorial Hospital, Bangkok, Thailand
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02191891
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇯🇵National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan
🇸🇬National Cancer Centre, Singapore, Singapore
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University College, London
- Target Recruit Count
- 12
- Registration Number
- NCT02183883
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centre (NHS Greater Glasgow & Clyde), Glasgow, United Kingdom
🇬🇧Aberdeen Royal Infirmary (NHS Grampian), Aberdeen, United Kingdom
🇬🇧Heart of England NHS Foundation Trust, Birmingham, United Kingdom
LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02131155
- Locations
- 🇨🇳
1200.162.86013 Boehringer Ingelheim Investigational Site, Jinan, China
🇨🇳1200.162.86007 Boehringer Ingelheim Investigational Site, Chengdu, China
🇰🇷1200.162.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.